Key Principles and Recommended Regimens for First-line Antiretroviral Therapy
Summary
- The phase III open-label FLAMINGO trial compared dolutegravir (n = 242) with darunavir + ritonavir (n = 242), each plus either abacavir/lamivudine or emtricitabine/tenofovir DF in treatment-naive patients[Clotet 2014]
- The dolutegravir regimen was found to be superior to the darunavir + ritonavir regimen at the Week 48 primary efficacy analysis with 90% vs 83%, respectively, achieving HIV-1 RNA < 50 copies/mL[Clotet 2014]
- The superior efficacy was maintained through Week 96 (80% vs 68% with HIV-1 RNA < 50 copies/mL, respectively)[Molina 2015]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content